[Drug-induced Stevens-Johnson syndrome in a patient with AIDS].
The Stevens-Johnson syndrome is a severe potentially life-threatening form of the erythema multiforme, affecting both skin and mucous membranes. We present a case of a 49-year-old male patient with AIDS who developed a Stevens-Johnson syndrome while being treated with pyrimethamine, sulfadiazine and phenytoin for cerebral toxoplasmosis. Further diagnostic evaluation of this dangerous cutaneous affection may prove difficult for several reasons. In particular, in patients with AIDS who are more susceptible for adverse drug reactions and who are simultaneously receiving a variety of drugs with a considerable potential of cutaneous side effects, therapy cannot be withhold for lack of therapeutic alternatives. Moreover, the low lymphocyte count in this case may have made reliable testing with lymphocyte transformation studies impossible. The evaluation and the differential diagnosis of the drug-induced Stevens-Johnson syndrome are discussed. Especially long- and moderately long-acting sulfonamides belong to the most important agents that can cause a drug-induced Stevens-Johnson syndrome. The pathogenesis and the risk factors for cutaneous hypersensitivity reactions in HIV-infected patients are only poorly understood. These kind of reactions, however, seem to occur more often in patients with a more advanced immunodeficiency.
Departement Innere Medizin, Kantonsspital Basel.
R G
RG
Schlienger
W E
WE
Haefeli
A
A
Bircher
S L
SL
Leib
T F
TF
Lüscher
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000009:adverse effects; D011739:Pyrimethamine / Q000009:adverse effects*; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000150:complications; D013411:Sulfadiazine / Q000009:adverse effects*; D016781:Toxoplasmosis, Cerebral / Q000188:drug therapy
D013411:Sulfadiazine; D010672:Phenytoin; D011739:Pyrimethamine